Proenkephalin A 119–159 (penKid) has been successfully integrated into daily practice in intensive care unit (ICU), demonstrating its effectiveness in assessing kidney function and predicting acute…
Practice-Oriented Management of Acute Dialysis in Cardiac Surgery Patients: Strategies and Challenges in Clinical Practice
Join Professor Bernardi from Vienna for an informative webinar on the…
Results from the first prospective study, conducted at the Medical University of Vienna, demonstrating penKid as a discriminatory biomarker for successful liberation from CRRT in cardiac surgery…
Our skilled international team has a breadth of experience in life sciences, disease biology, biotechnology, and clinical in vitro diagnostics and is dedicated to supporting the medical community and…
Through this collaboration, the companies will bring an assay for SphingoTec’s innovative kidney function biomarker, Proenkephalin 119-159 (penKid), to Beckman Coulter’s extensive test menu for use…
SphingoTec announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its…
SphingoTec introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to…
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
